~~<i id='CFA1373301'><strike id='CFA1373301'><tt id='CFA1373301'><pre id='CFA1373301'></pre></tt></strike></i>~~

Home» focus» entertainment

entertainment

author：comprehensive 2025-10-06 14:48:40 Page View：2898

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi
Next article： Activists slam private health insurers over coverage restrictions

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

ScientistFengZhang,right,isinterviewedbyreporterMeganMolteniatSTAT'sBreakthroughSummitEast.STATWhent

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Tabernantheiboga,theshrubthatcontainsthepsychedelicsubstanceibogaine.WikimediaCommonsThepsychedelici